Howard Hughes Holdings Inc. Announces Dates and Times for 2024 Third Quarter Earnings Release and Conference Call
THE WOODLANDS, Texas, Oct. 09, 2024 (GLOBE NEWSWIRE) — Howard Hughes Holdings Inc. (NYSE: HHH) (“the Company” or “Howard Hughes”) […]
Springbig Launches Innovative MP5 Messaging Feature with Remarkable Beta Test Results
BOCA RATON, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) — Springbig, the leading provider of loyalty and marketing solutions for the […]
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for […]
SemiCab Wins Major New Contract with $10 Billion Indian Consumer Packaged Goods Company for New Pilot in India
Multinational Consumer Goods Company Enters into aCommercially Scalable Pilot with SemiCab Serving the Indian Market Fort Lauderdale, FL, Oct. 09, […]
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is […]
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted […]
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to […]
Marex Agrees Terms to Acquire UK FX Specialist Hamilton Court Group
LONDON, Oct. 09, 2024 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial […]
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports […]
TSX News -
Bird Construction Announces 50% Dividend Increase and Releases 2025-2027 Financial Targets
MISSISSAUGA, Ontario, Oct. 09, 2024 (GLOBE NEWSWIRE) — Bird Construction Inc. (TSX: BDT) will host its 2024 Investor Day in […]
